Stocklytics Platform
Asset logo for symbol MNOV
MediciNova
MNOV44
$1.66arrow_drop_down3.46%-$0.06
Penny Stock
Asset logo for symbol MNOV
MNOV44

$1.66

arrow_drop_down3.46%

Performance History

Chart placeholder
Key Stats
Open$1.71
Prev. Close$1.73
EPS-0.16
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$81.90M
PE Ratio-
LOWHIGH
Day Range1.61
1.76
52 Week Range1.12
2.16
Ratios
EPS-0.16

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

About MediciNova (MNOV)

MediciNova Inc. (MNOV) is a publicly traded biopharmaceutical company that focuses on the development of novel small molecule therapeutics for the treatment of serious diseases. The company's mission is to improve the lives of patients by developing innovative medicines that target unmet medical needs. MediciNova's pipeline of drug candidates includes potential treatments for asthma, multiple sclerosis, fibrosis, and other inflammatory diseases. The company's lead product candidate, MN-166 (ibudilast), is being developed for the treatment of progressive multiple sclerosis (MS) and other neurological conditions. MN-166 is currently in Phase 3 clinical trials for MS and Phase 2 trials for amyotrophic lateral sclerosis (ALS) and chemotherapy-induced peripheral neuropathy (CIPN).
MediciNova's stock price history shows a fluctuation in value over time, with periods of both growth and decline. The stock has experienced several significant price increases and decreases in line with the company's clinical trial results and other news announcements. Investors should carefully consider the risks and potential rewards associated with investing in MediciNova stock, as the biopharmaceutical industry can be volatile and unpredictable. It is important to conduct thorough research and analysis before making any investment decisions. MediciNova's market capitalization, or market cap, is the total value of the company's outstanding shares of stock. The market cap is calculated by multiplying the current stock price by the number of outstanding shares. This figure provides investors with an indication of the size and value of the company.
Websitecall_made
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Yuichi Iwaki M.D., Ph.D.
Headquarters
La Jolla
Employees
13
Exchange
NASDAQ
add MediciNova to watchlist

Keep an eye on MediciNova

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is MediciNova 's (MNOV) price per share?

The current price per share for MediciNova (MNOV) is $1.66. The stock has seen a price change of -$0.06 recently, indicating a -3.47% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for MediciNova (MNOV)?

For MediciNova (MNOV), the 52-week high is $2.16, which is 30.12% from the current price. The 52-week low is $1.12, the current price is 48.21% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is MediciNova (MNOV) a growth stock?

MediciNova (MNOV) has shown an average price growth of -3.37% over the past three years. It has received a score of 23 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying MediciNova as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is MediciNova (MNOV) stock price performance year to date (YTD)?

As of the latest data, MediciNova (MNOV) has a year-to-date price change of 0.61%. Over the past month, the stock has experienced a price change of -12.17%. Over the last three months, the change has been 26.72%. Over the past six months, the figure is 26.72%. Looking at a longer horizon, the five-year price change stands at -77.93%.
help

Is MediciNova (MNOV) a profitable company?

MediciNova (MNOV) has a net income of -$8.57M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -981.95% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $1M, although specific revenue growth data is currently not available. The gross profit is $979.7K. Operating income is noted at -$9.9M. Furthermore, the EBITDA is -$9.8M.
help

What is the market capitalization of MediciNova (MNOV)?

MediciNova (MNOV) has a market capitalization of $84.85M. The average daily trading volume is 1.67, indicating the stock's liquidity and investor engagement.

News

MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)
MEDICINOVA
MN-166
IBUDILAST
AMYOTROPHIC LATERAL SCLEROSIS
ALS
EXPANDED ACCESS PROTOCOL
EAP
NIH
NINDS
Sep 30, 2024

MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND
MEDICINOVA
MN-166
IBUDILAST
COMBAT-ALS
ALS
CLINICAL TRIAL
Sep 9, 2024

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND

MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting
MEDICINOVA
MN-166
IBUDILAST
COMBAT-ALS
NEALS
Sep 3, 2024

MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting

MediciNova Chief Business Officer David H. Crean, Ph.D. Assumes Communications Role Overseeing Investor Engagement and Public Relations
DIRECTORS AND OFFICERS
PRODUCT / SERVICES ANNOUNCEMENT
Jun 20, 2024

MediciNova Chief Business Officer David H. Crean, Ph.D. Assumes Communications Role Overseeing Investor Engagement and Public Relations

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer
PATENTS
Jun 5, 2024

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer

MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024
RESEARCH ANALYSIS AND REPORTS
CLINICAL STUDY
Jun 3, 2024

MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level